News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The approval bolsters the company's Mycophenolate Mofetil portfolio
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Subscribe To Our Newsletter & Stay Updated
